Singapore eDevelopment subsidiary starts advanced research on Linebacker

Singapore eDevelopment subsidiary Global BioLife has started advanced research on a new universal therapeutic drug platform called Linebacker to tackle multiple conditions such as Alzheimer's, diabetes, and cancer.  

Research will be led by Daryl Thompson as the director of scientific initiatives, who will use his knowledge of organic and carbohydrate chemistry, along with pandemic technology in combating the Ebola virus to develop the new drug platform.

Global BioLife research coordinator and special projects leader Scott Truesdell will execute the research on the Linebacker platform.

The Linebacker platform intends to develop a breakthrough option to cure multiple diseases instead of treating individual diseases with specific drugs.

SeD owns 80% in Global BioLife, while Thompson's GRDG Sciences and Holista CollTech each hold 10%. 

"We are targeting for the platform to be completed within 12 months."

Thompson said: "We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within 12 months. 

"We have a unique patented technology and are already getting interest from big pharma players and venture capitalists.

"This interest will rise as the validating data becomes available." 

Daryl Thompson has researched on organic and carbohydrate chemistry and also studied pandemics technology to fight Ebola. 

Global BioLife has also associated itself with Charles River Laboratories International that provides essential products and services to help pharmaceutical and biotechnology companies in their research and drug development programmes.